ArticleForensic toxicology2026
Quantitative analysis and method validation of mirogabalin in postmortem blood and urine using liquid chromatography-tandem mass spectrometry.
Article in Forensic toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMirogabalin is a gabapentinoid used to treat peripheral neuropathic pain. While its adverse effect profile is generally mild, postmortem toxicological data are currently unavailable. This study aimed to develop and validate a quantitative method for determining mirogabalin concentrations in postmortem blood and urine using liquid chromatography–tandem mass spectrometry (LC-MS/MS), and to evaluate its concentrations in a fatal multiple drug intoxication case involving mirogabalin.
methodsPostmortem blood and urine specimens were collected during a forensic autopsy following a mirogabalin overdose. For method development and validation, blank blood and urine samples were spiked with mirogabalin standard solutions. Mirogabalin was extracted using the QuEChERS method, further purified using Captiva ND Lipids cartridges, and analyzed by LC-MS/MS. The method was validated according to the U.S. Food and Drug Administration bioanalytical guideline.
resultsThe method demonstrated good linearity over the range of 0.2–100 µg/mL (r > 0.99), with an LLOQ of 0.1 µg/mL. Mirogabalin concentrations in postmortem blood and urine were 1.99 µg/mL and 3.56 µg/mL, respectively. Accuracy and precision were within acceptable limits. Matrix effects were observed, indicating ion suppression. Recovery rates were generally within the recommended range. Mirogabalin also showed sufficient stability.
conclusionsThis is the first study to establish and validate an LC-MS/MS method for quantifying mirogabalin in postmortem blood and urine. The findings provide valuable data for forensic toxicological interpretation and evaluation of fatal intoxication cases associated with mirogabalin.
Indexed as
Identifiers
41870671What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.